Malignant Conjunctival Melanoma: A Case Report Study
DOI:
https://doi.org/10.69980/ajpr.v28i1.190Keywords:
Conjunctival melanoma, Pigmented tumors, Orbital exenteration, Recurrence, Cameroon.Abstract
Context: Melanocytic lesions are the most common tumors of the conjunctiva and are known for their recurrent potential. The aim of our study was to present the clinical and therapeutic evolution of a case of conjunctival melanoma managed in our healthcare facility. Case Presentation: We report the case of a 28-year-old male businessman who presented with a large, lobulated, and heavily pigmented lesion located in the superior and inferior fornices, initially suspected to be a recurrent nevus. Clinical and radiological assessments led to the diagnosis of conjunctival melanoma. Despite orbital exenteration and adjuvant chemotherapy, a recurrence of the tumor was observed five months after treatment. Discussion: This case highlights the therapeutic challenges and the lack of understanding regarding the molecular mechanisms underlying the recurrent nature of conjunctival melanoma, despite surgical and chemotherapeutic interventions. A deeper exploration of poor prognostic factors may enhance our understanding of these recurrence and guide us toward new therapeutic strategies. Conclusion: Conjunctival melanoma remains a malignant tumor with complex therapeutic management, and its recurrent mechanisms are yet to be fully understood.
References
1. Shields CL, Lally SE, Shields JA. A Guide to Conjunctival Tumors: These are benign half the time--but when they are malignant, you need to be ready to refer. Rev Optom 2019 ;156(5):50‑7.
2. Lim LA, Madigan ,Michele C, and Conway RM. Conjunctival melanoma: a review of conceptual and treatment advances. Clin Ophthalmol 2013 ;7:521‑31.
3. Shields CL, Shields JA, Gündüz K, Cater J, Mercado GV, Gross N, Lally B. Conjunctival Melanoma: Risk Factors for Recurrence, Exenteration, Metastasis, and Death in 150 Consecutive Patients. Arch Ophthalmol. 2000 ;118(11):1497‑507.
4. Butt K, Hussain R, Coupland SE, Krishna Y. Conjunctival melanoma: a clinical review and update. Cancers 2024;16(18):3121.
5. Wong JR, Nanji AA, Galor A, Karp CL. Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol. 2014;9(3):185‑204.
6. Zeiger JS, Lally SE, Dalvin LA, Shields CL. Advances in conjunctival melanoma: clinical features, diagnostic modalities, staging, genetic markers, and management. Can J Ophthalmol 2024;59(4):209‑17.
7. Nahon-Estève S, Bertolotto C, Picard-Gauci A, Gastaud L, Baillif S, Hofman P, Groulier A, Maschi C, Caujolle JP, Lassalle S, Martel A. Small but Challenging Conjunctival Melanoma: New Insights, Paradigms and Future Perspectives. Cancers. 14 nov 2021;13(22):5691.
8. Dębicka-Kumela M, Romanowska-Dixon B, Karska-Basta I, Kowal J, Pociej-Marciak W, Markiewicz A. Diagnostic Algorithm for Conjunctival Melanocytic Lesions. Anticancer Res 2021;41(6):3161‑7.
9. Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Süsskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP, Schadendorf D. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(12):3143‑52.
10. León-Letelier RA, Bonifaz LC, Fuentes-Pananá EM. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy. J Leukoc Biol [Internet]. 2019;105(5):915‑33. Disponible sur: https://doi.org/10.1002/JLB.MR0618-241RR
11. Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020;17(3):137‑50.
12. Larsen AC. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile. Acta Ophthalmol (Copenh). 2016 ;94(A103):1‑27.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 American Journal of Psychiatric Rehabilitation
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License permitting all use, distribution, and reproduction in any medium, provided the work is properly cited.
